

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2017/0002804				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
PALABRAS CLAVE UTILIZADAS		Dpr and antibodies and c9orf72, pd<20140930 Dipeptide repeat antibody		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 16/18, G01N 33/53, A61K 39/395.		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA(EPO)	wo2014/114303	31/07/2014	NA	A
	Mori et al.	07/02/2013	NA	A
	Mackenzie et al.	01/12/2013	NA	A
Ncbi (SEQs: 4, 6, 10, 12, 24, 28, 32, 36, 16, 20, 46, 50, 74, 78, 54, 40, 42, 66, 70, 82, 86, 2, 8, 22, 26, 30, 34, 14, 18, 44, 48, 72, 76, 52, 56, 38, 64, 68, 80, 84)	NA			
epoquet	NA			
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	KOHJI MORI, SHIH-MING WENG, THOMAS ARZBERGER, STEPHANIE MAY, KRISTIN RENTZSCH, ELISABETH KREMMER, BETTINA SCHMID, HANS A. KRETZSCHMAR, MARC CRUTS, CHRISTINE VAN BROECKHOVEN, CHRISTIAN HAASS, DIETER EDBAUER (2013) The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTL/ALS. Science 07 Feb 2013: DOI: 10.1126/science.1232927
--	--

Fecha del reporte de búsqueda:	07/04/2018
---------------------------------------	------------

UNIDAD DE INVENCION

Porcentajes de identidad entre las secuencias variables ligeras reclamadas en la invención:

[illegible]

Porcentajes de identidad entre las secuencias variables pesadas VH reclamadas en la invención:

[illegible]

Buscador	Epoquenet - Epodoc
----------	--------------------

[EPODOC: SS 1] dpr

Results in EPODOC **291**

[SS 2] 1 and antibody

Results in EPODOC **8**

[SS 3] 2 and c9orf72

Results in EPODOC **6**

[SS 4] 3 and pd<20140930

Results in EPODOC **0**

Buscador	NCBI-patented sequences
Query:	SEQs: 4, 6, 10, 12, 24, 28, 32, 36, 16, 20, 46, 50, 74, 78, 54, 40, 42, 66, 70, 82, 86, 2, 8, 22, 26, 30, 34, 14, 18, 44, 48, 72, 76, 52, 56, 38, 64, 68, 80, 84
Entrez term	C9ORF72

BLAST Results

Your search is limited to records that include: entrez query: c9orf72 [Full Entrez Query](#)

[Edit and Resubmit](#) [Save Search Strategies](#) [Formatting options](#) [Download](#) [YouTube](#) [How to read this page](#) [Blast report](#)

Download

Alignment
[Text](#) [XML](#) [ASN.1](#) [JSON Seq-align](#) [Multiple-file XML2](#)
[Single-file XML2](#) [Multiple-file JSON](#) [Single-file JSON](#)

Search Strategies
[ASN.1](#)

Job title: 40 sequences (WO2016050822_2)

Results for: *1:Id|Query_253526 WO2016050822_2(123aa) [Download](#)

RID [CNNBNK9N014](#) (Expires on 04-10 10:52 am)

Query ID	Id Query_253526	Database Name	pat
Description	WO2016050822_2	Description	Protein sequences derived from the Patent GenBank
Molecule type	amino acid	Program	BLASTP 2.8.0+ Citation
Query Length	123		

No significant similarity found. For reasons why, [click here](#)

Buscador	LENS- FINDER
Query:	SEQs: 4, 6, 10, 12, 24, 28, 32, 36, 16, 20, 46, 50, 74, 78, 54, 40, 42, 66, 70, 82, 86, 2, 8, 22, 26, 30, 34, 14, 18, 44, 48, 72, 76, 52, 56, 38, 64, 68, 80, 84
FILTER	Before 30/09/2014

Patent Number	Title	Publication Date	SEQ ID NO	Local % Id
US 2004 0018198 A1	Antibodies against carbonic anydrase IX (CA IX) tumor antigen	29/01/04	3	86.1%
US 2004 0018198 A1	Antibodies against carbonic anydrase IX (CA IX) tumor antigen	29/01/04	6	86.1%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	3	86.1%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	6	86.1%
JP 2005538682 A		22/12/05	93	86.1%
JP 2005538682 A		22/12/05	96	86.1%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	3	86.1%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	6	86.1%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	318	85.2%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	222	86.%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	282	82.4%

US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	4	85.2%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	102	85.2%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	4	85.2%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	102	85.2%
JP 2005538682 A		22/12/05	92	85.2%
JP 2005538682 A		22/12/05	94	85.2%
JP 2005538682 A		22/12/05	192	85.2%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	2	85.2%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	4	85.2%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	102	85.2%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	126	84.4%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	126	84.4%
JP 2005538682 A		22/12/05	196	84.4%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	126	84.4%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	52	83.9%
US 2011 0135657 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	09/06/11	75	85.4%
JP 2013512689 A		18/04/13	217	85.4%
WO 2011 071783 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	75	85.4%
CA 2981687 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND .BETA.-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	75	85.4%

CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	62	83.9%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	64	84.%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	66	84.%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	50	83.1%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	366	81.5%
US 2012 0207760 A1	Compositions and Methods for the Therapy and Diagnosis of Influenza	16/08/12	984	82.5%
US 2012 0039899 A1	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof	16/02/12	243	82.5%
JP 2013540701 A		07/11/13	337	82.5%
JP 2014506580 A		17/03/14	1092	82.5%
EP 2603237 A2	ANTI-HEMAGGLUTININ ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF	19/06/13	243	82.5%
EP 2675478 A2	COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA	25/12/13	984	82.5%
KR 20140012098 A	COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA	29/01/14	984	82.5%
WO 2012 021786 A2	ANTI-HEMAGGLUTININ ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF	16/02/12	243	82.5%
WO 2012 112489 A2	COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA	23/08/12	984	82.5%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	54	83.1%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	72	83.1%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	58	83.1%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the	21/12/06	110	83.1%

	treatment of inflammation and other disorders			
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	56	83.1%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	2	85.%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	2	85.%
US 2011 0044986 A1	ANTI-AMYLOID ANTIBODIES AND USES THEREOF	24/02/11	83	82.8%
US 8414893 B2	Anti-amyloid antibodies and uses thereof	09/04/13	83	82.8%
WO 2009 085200 A2	ANTI-AMYLOID ANTIBODIES AND USES THEREOF	09/07/09	83	82.8%
EP 2261254 A2	Anti-amyloid antibodies and uses thereof	15/12/10	83	82.8%
CA 2709354 C	ANTI-AMYLOID ANTIBODIES AND USES THEREOF	17/06/14	83	82.8%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	48	82.3%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	134	82.8%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	134	82.8%
JP 2005538682 A		22/12/05	204	82.8%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	134	82.8%
US 2011 0135657 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	09/06/11	74	84.6%
JP 2013512689 A		18/04/13	216	84.6%
WO 2011 071783 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	74	84.6%
CA 2981687 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND .BETA.-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	74	84.6%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	18	82.%

US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	238	83.5%
CA 2871750 A1	HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS	31/10/13	60	82.3%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	290	81.6%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	322	81.6%
US 2008 0124345 A1	Antibodies directed to HER-3 and uses thereof	29/05/08	40	83.7%
US 2010 0183631 A1	Antibodies Directed to HER-3 and Uses Thereof	22/07/10	40	83.7%
US 2011 0229406 A1	Material and methods for treating or preventing HER-3 associated diseases	22/09/11	40	83.7%
US 2012 0058122 A1	Antibodies Directed to HER-3 and Uses Thereof	08/03/12	40	83.7%
US 2012 0156130 A1	USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT	21/06/12	40	83.7%
US 2014 0017166 A1	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	16/01/14	40	83.7%
US 7705130 B2	Antibodies directed to HER-3 and uses thereof	27/04/10	40	83.7%
US 8771695 B2	Antibodies directed to HER-3 and uses thereof	08/07/14	40	83.7%
WO 2007 077028 A2	ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF	12/07/07	40	83.7%
JP 2009521913 A		11/06/09	138	83.7%
JP 2013056884 A	ANTIBODY DIRECTED TO HER-3 AND USE THEREOF	28/03/13	138	83.7%
JP 2013510868 A		28/03/13	139	83.7%
JP 2014012006 A	ANTIBODY INDUCED AGAINST HER-3 AND USE THEREOF	23/01/14	138	83.7%
JP 2013540694 A		07/11/13	139	83.7%
WO 2011 060206 A2	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	19/05/11	40	83.7%

WO 2012 018404 A2	USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT	09/02/12	40	83.7%
WO 2013 124419 A1	HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY	29/08/13	40	83.7%
CA 2780935 A1	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	19/05/11	40	83.7%
CA 2865256 A1	HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY	29/08/13	40	83.7%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	79	83.6%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	79	83.6%
JP 2005538682 A		22/12/05	169	83.6%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	79	83.6%
US 2006 0093600 A1	Antibodies to CD40	04/05/06	18	83.6%
US 2007 0190051 A1	Antibodies to CD40	16/08/07	18	83.6%
US 2009 0130715 A1	Antibodies to CD40	21/05/09	18	83.6%
US 2009 0169563 A1	Antibodies to CD40	02/07/09	18	83.6%
US 2010 0098694 A1	ANTIBODIES TO CD40	22/04/10	18	83.6%
US 2012 0225014 A1	ANTIBODIES TO CD40	06/09/12	18	83.6%
US 2013 0024956 A1	ANTIBODIES TO CD40	24/01/13	18	83.6%
US 7288251 B2	Antibodies to CD40	30/10/07	18	83.6%
US 7338660 B2	Methods of treating cancer and enhancing immune responses with antibodies that bind CD40	04/03/08	18	83.6%
US 7563442 B2	Antibodies to CD40 and methods of treating cancer and enhancing immune responses	21/07/09	18	83.6%
US 7618633 B2	Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses	17/11/09	18	83.6%
US 7626012 B2	Nucleic acid molecules which encode antibodies that bind CD40	01/12/09	18	83.6%
US 8388971 B2	Antibodies that bind CD40 and methods of treating	05/03/13	18	83.6%

	cancer and enhancing immune responses			
JP 2005508176 A		31/03/05	84	83.6%
JP 2010213704 A	ANTIBODY TO CD40	30/09/10	84	83.6%
JP 2013099333 A	ANTIBODY TO CD40	23/05/13	84	83.6%
EP 2343086 A2	Antibodies to CD40	13/07/11	18	83.6%
KR 100830086 B1	ANTIBODIES TO CD40	20/05/08	18	83.6%
CA 2466128 C	ANTIBODIES TO CD40	29/10/13	18	83.6%
US 2004 0018198 A1	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	29/01/04	100	83.6%
US 7378091 B2	Antibodies against carbonic anhydrase IX (CA IX) tumor antigen	27/05/08	100	83.6%
JP 2005538682 A		22/12/05	190	83.6%
CA 2467738 A1	ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX (CA IX) TUMOR ANTIGEN	12/06/03	100	83.6%
US 2006 0002929 A1	Monoclonal antibodies	05/01/06	6	83.3%
JP 2007530045 A		01/11/07	14	83.3%
WO 2005 094879 A2	MONOCLONAL ANTIBODIES	13/10/05	6	83.3%
CA 2560889 A1	MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN OX40L (CD 134L)	13/10/05	6	83.3%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	234	80.8%
US 2008 0219979 A1	Methods of using IL-17 receptor A antibodies	11/09/08	23	81.6%
US 2008 0220479 A1	Polynucleotides encoding IL-17 receptor a antigen binding proteins	11/09/08	23	81.6%
US 2008 0221307 A1	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	11/09/08	23	81.6%
US 2009 0074758 A1	IL-17 receptor a antigen binding proteins	19/03/09	23	81.6%
US 2010 0028345 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/02/10	23	81.6%
US 2010 0292442 A1	ANTI-IL-17 RECEPTOR A NEUTRALIZING ANTIBODIES	18/11/10	23	81.6%
US 2011 0008841 A1	POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	13/01/11	23	81.6%
US 2011 0052600 A1	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/03/11	23	81.6%

US 2011 0081339 A1	METHODS OF USING IL-17 RECEPTOR A ANTIBODIES	07/04/11	23	81.6%
US 2011 0166331 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	07/07/11	23	81.6%
US 2012 0251547 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/10/12	23	81.6%
US 2012 0308566 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	06/12/12	23	81.6%
US 7767206 B2	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	03/08/10	23	81.6%
US 7786284 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	31/08/10	23	81.6%
US 7833527 B2	Methods of treating psoriasis using IL-17 Receptor A antibodies	16/11/10	23	81.6%
US 7939070 B2	IL-17 receptor A antigen binding proteins	10/05/11	23	81.6%
US 8435518 B2	Methods of using IL-17 receptor a antibodies	07/05/13	23	81.6%
US 8545842 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	01/10/13	23	81.6%
US 8790648 B2	Methods of treating psoriasis using IL-17 receptor A antibodies	29/07/14	23	81.6%
JP 2010505416 A		25/02/10	237	81.6%
WO 2008 054603 A2	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	08/05/08	23	81.6%
JP 2011514335 A		06/05/11	23	81.6%
WO 2009 136976 A2	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	12/11/09	23	81.6%
JP 2014122231 A	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/07/14	23	81.6%
WO 2011 046958 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	23	81.6%
CA 2776712 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	23	81.6%
US 2013 0004501 A1	HUMAN IL-23 ANTIGEN BINDING PROTEINS	03/01/13	44	82.8%
US 2014 0212428 A1	HUMAN IL-23 ANTIGEN BINDING PROTEINS	31/07/14	44	82.8%
US 8722033 B2	Human IL-23 antigen binding proteins	13/05/14	44	82.8%
JP 2013507991 A		07/03/13	57	82.8%
WO 2011 056600 A1	HUMAN IL-23 ANTIGEN BINDING PROTEINS	12/05/11	44	82.8%

CA 2778112 A1	HUMAN IL-23 ANTIGEN BINDING PROTEINS	12/05/11	44	82.8%
US 2014 0004121 A1	ANTI-MESOTHELIN BINDING PROTEINS	02/01/14	89	80.5%
WO 2014 004549 A2	ANTI-MESOTHELIN BINDING PROTEINS	03/01/14	89	80.5%
US 2011 0135657 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	09/06/11	39	85.4%
JP 2013512689 A		18/04/13	181	85.4%
WO 2011 071783 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	39	85.4%
CA 2981687 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND .BETA.-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	39	85.4%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1795	84.7%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2134	84.7%
JP 2012508016 A		05/04/12	2802	84.7%
JP 2013510164 A		21/03/13	2141	84.7%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1795	84.7%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2134	84.7%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1795	84.7%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2134	84.7%
US 2007 0098715 A1	Antibodies against the tenascin major antigens	03/05/07	6	81.1%
JP 2008535823 A		04/09/08	29	81.1%
WO 2006 104978 A2	ANTIBODIES AGAINST THE TENASCIN MAJOR ANTIGENS	05/10/06	6	81.1%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	274	80.8%

US 2006 0246071 A1	Antibodies directed to angiopoietin-2 and uses thereof	02/11/06	589	84.4%
US 2008 0267971 A1	Antibodies Directed to Angiopoietin-2 and Uses Thereof	30/10/08	589	84.4%
US 2012 0052073 A1	Antibodies Directed to Angiopoietin-2 And Uses Thereof	01/03/12	589	84.4%
US 2013 0171160 A1	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	04/07/13	589	84.4%
US 7973140 B2	Antibodies directed to angiopoietin-2 and uses thereof	05/07/11	589	84.4%
US 8834880 B2	Antibodies directed to angiopoietin-2 and uses thereof	16/09/14	589	84.4%
JP 2008523841 A		10/07/08	589	84.4%
WO 2006 068953 A2	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	29/06/06	589	84.4%
JP 2012050455 A	ANTIBODY DIRECTED TO ANGIOPOIETIN-2 AND USE THEREOF	15/03/12	589	84.4%
EP 2284194 A1	Antibodies directed to angiopoietin-2 and uses thereof	16/02/11	589	84.4%
CA 2595610 C	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	05/03/13	589	84.4%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	226	80.%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	334	79.2%
US 2008 0219979 A1	Methods of using IL-17 receptor A antibodies	11/09/08	5	82.4%
US 2008 0220479 A1	Polynucleotides encoding IL-17 receptor a antigen binding proteins	11/09/08	5	82.4%
US 2008 0221307 A1	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	11/09/08	5	82.4%

US 2009 0074758 A1	IL-17 receptor a antigen binding proteins	19/03/09	5	82.4%
US 2010 0028345 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/02/10	5	82.4%
US 2010 0292442 A1	ANTI-IL-17 RECEPTOR A NEUTRALIZING ANTIBODIES	18/11/10	5	82.4%
US 2011 0008841 A1	POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	13/01/11	5	82.4%
US 2011 0052600 A1	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/03/11	5	82.4%
US 2011 0081339 A1	METHODS OF USING IL-17 RECEPTOR A ANTIBODIES	07/04/11	5	82.4%
US 2011 0166331 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	07/07/11	5	82.4%
US 2012 0251547 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/10/12	5	82.4%
US 2012 0308566 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	06/12/12	5	82.4%
US 7767206 B2	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	03/08/10	5	82.4%
US 7786284 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	31/08/10	5	82.4%
US 7833527 B2	Methods of treating psoriasis using IL-17 Receptor A antibodies	16/11/10	5	82.4%
US 7939070 B2	IL-17 receptor A antigen binding proteins	10/05/11	5	82.4%
US 8435518 B2	Methods of using IL-17 receptor a antibodies	07/05/13	5	82.4%
US 8545842 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	01/10/13	5	82.4%
US 8790648 B2	Methods of treating psoriasis using IL-17 receptor A antibodies	29/07/14	5	82.4%
JP 2010505416 A		25/02/10	219	82.4%
WO 2008 054603 A2	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	08/05/08	5	82.4%
JP 2011514335 A		06/05/11	5	82.4%
WO 2009 136976 A2	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	12/11/09	5	82.4%
JP 2014122231 A	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/07/14	5	82.4%

WO 2011 046958 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	5	82.4%
CA 2776712 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	5	82.4%
US 2003 0054407 A1	Structure-based construction of human antibody library	20/03/03	5	81.1%
US 2005 0148001 A1	Structure-based construction of human antibody library	07/07/05	5	81.1%
US 2006 0003334 A1	Protein (poly)peptides libraries	05/01/06	39	81.1%
US 2006 0003334 A1	Protein (poly)peptides libraries	05/01/06	65	81.1%
US 2006 0165682 A1	Humanized antibodies that recognize beta amyloid peptide	27/07/06	25	81.1%
US 2006 0198851 A1	Humanized Abeta antibodies for use in improving cognition	07/09/06	49	81.1%
US 2006 0257396 A1	Abeta antibodies for use in improving cognition	16/11/06	84	81.1%
US 2008 0026948 A1	Protein (poly)peptides libraries	31/01/08	39	81.1%
US 2008 0026948 A1	Protein (poly)peptides libraries	31/01/08	65	81.1%
US 2009 0252733 A1	Generation and Profiling of Fully Human Gold-Derived Therapeutic Antibodies Specific for Human CD38	08/10/09	64	81.1%
US 2011 0257044 A1	Structure-based construction of human antibody library	20/10/11	5	81.1%
US 2012 0052078 A1	GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38	01/03/12	64	81.1%
US 2013 0273072 A1	FULLY HUMAN THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38	17/10/13	64	81.1%
US 6696248 B1	Protein/(poly)peptide libraries	24/02/04	39	81.1%
US 6696248 B1	Protein/(poly)peptide libraries	24/02/04	65	81.1%
US 6706484 B1	Protein/(poly)peptide libraries	16/03/04	39	81.1%
US 6706484 B1	Protein/(poly)peptide libraries	16/03/04	65	81.1%
US 6828422 B1	Protein/(poly)peptide libraries	07/12/04	39	81.1%
US 6828422 B1	Protein/(poly)peptide libraries	07/12/04	65	81.1%
US 7264963 B1	Protein(poly)peptide libraries	04/09/07	39	81.1%

US 7264963 B1	Protein(poly)peptide libraries	04/09/07	65	81.1%
US 7625560 B2	Humanized antibodies that recognize beta amyloid peptide	01/12/09	25	81.1%
US 8088896 B2	Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38	03/01/12	64	81.1%
US 8486394 B2	Generation and Profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38	16/07/13	64	81.1%
US 8513164 B2	Protein (poly)peptides libraries	20/08/13	39	81.1%
US 8513164 B2	Protein (poly)peptides libraries	20/08/13	65	81.1%
WO 1997 008320 A1	PROTEIN/(POLY)PEPTIDE LIBRARIES	06/03/97	39	81.1%
WO 1997 008320 A1	PROTEIN/(POLY)PEPTIDE LIBRARIES	06/03/97	65	81.1%
JP 2008523815 A		10/07/08	51	81.1%
JP 2008524247 A		10/07/08	86	81.1%
WO 2006 066171 A1	AMYLOID ???? ANTIBODIES FOR USE IN IMPROVING COGNITION	22/06/06	84	81.1%
WO 2006 066089 A1	HUMANIZED AMYLOID BETA ANTIBODIES FOR USE IN IMPROVING COGNITION	22/06/06	49	81.1%
WO 2006 066049 A2	HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE	22/06/06	25	81.1%
JP 2009511033 A		19/03/09	98	81.1%
WO 2007 042309 A2	GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38	19/04/07	64	81.1%
JP 2010246549 A	PROTEIN/(POLY)PEPTIDE LIBRARY	04/11/10	253	81.1%
JP 2010246549 A	PROTEIN/(POLY)PEPTIDE LIBRARY	04/11/10	267	81.1%
JP 2010029198 A	PROTEIN/(POLY)PEPTIDE LIBRARY	12/02/10	253	81.1%
JP 2010029198 A	PROTEIN/(POLY)PEPTIDE LIBRARY	12/02/10	267	81.1%
JP 2012024098 A	HUMANIZED AMYLOID β ANTIBODY FOR USE IN IMPROVING COGNITION	09/02/12	51	81.1%

JP 2012233002 A	AMYLOID BETA ANTIBODY FOR USE IN IMPROVING COGNITION	29/11/12	86	81.1%
KR 20080068056 A	GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38	22/07/08	64	81.1%
US 6300064 B1	Protein/(poly)peptide libraries	09/10/01	39	81.1%
US 6300064 B1	Protein/(poly)peptide libraries	09/10/01	65	81.1%
CA 2589017 A1	AMYLOID BETA ANTIBODIES FOR USE IN IMPROVING COGNITION	22/06/06	84	81.1%
CA 2443862 A1	STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY	24/10/02	5	81.1%
US 2006 0286112 A1	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders	21/12/06	162	83.6%
US 2009 0155164 A1	HUMAN C-FMS ANTIGEN BINDING PROTEINS	18/06/09	91	79.5%
US 2012 0230987 A1	METHODS FOR TREATING CONDITIONS ASSOCIATED WITH C-FMS	13/09/12	91	79.5%
US 2014 0105916 A1	HUMAN C-FMS ANTIGEN BINDING PROTEINS	17/04/14	91	79.5%
US 8182813 B2	Human C-FMS antigen binding proteins	22/05/12	91	79.5%
US 8513199 B2	Methods for treating conditions associated with c-fms	20/08/13	91	79.5%
JP 2010536378 A		02/12/10	152	79.5%
WO 2009 026303 A1	HUMAN C-FMS ANTIGEN BINDING PROTEINS	26/02/09	91	79.5%
EP 2589610 A1	Human c-fms antigen binding proteins	08/05/13	91	79.5%
EP 2592093 A1	Human c-fms antigen binding proteins	15/05/13	91	79.5%
US 2008 0219979 A1	Methods of using IL-17 receptor A antibodies	11/09/08	24	80.8%
US 2008 0220479 A1	Polynucleotides encoding IL-17 receptor a antigen binding proteins	11/09/08	24	80.8%
US 2008 0221307 A1	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	11/09/08	24	80.8%

US 2009 0074758 A1	IL-17 receptor a antigen binding proteins	19/03/09	24	80.8%
US 2010 0028345 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/02/10	24	80.8%
US 2010 0292442 A1	ANTI-IL-17 RECEPTOR A NEUTRALIZING ANTIBODIES	18/11/10	24	80.8%
US 2011 0008841 A1	POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	13/01/11	24	80.8%
US 2011 0052600 A1	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/03/11	24	80.8%
US 2011 0081339 A1	METHODS OF USING IL-17 RECEPTOR A ANTIBODIES	07/04/11	24	80.8%
US 2011 0166331 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	07/07/11	24	80.8%
US 2012 0251547 A1	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	04/10/12	24	80.8%
US 2012 0308566 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	06/12/12	24	80.8%
US 7767206 B2	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto	03/08/10	24	80.8%
US 7786284 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	31/08/10	24	80.8%
US 7833527 B2	Methods of treating psoriasis using IL-17 Receptor A antibodies	16/11/10	24	80.8%
US 7939070 B2	IL-17 receptor A antigen binding proteins	10/05/11	24	80.8%
US 8435518 B2	Methods of using IL-17 receptor a antibodies	07/05/13	24	80.8%
US 8545842 B2	Polynucleotides encoding IL-17 receptor A antigen binding proteins	01/10/13	24	80.8%
US 8790648 B2	Methods of treating psoriasis using IL-17 receptor A antibodies	29/07/14	24	80.8%
JP 2010505416 A		25/02/10	238	80.8%
WO 2008 054603 A2	IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	08/05/08	24	80.8%
JP 2011514335 A		06/05/11	24	80.8%
WO 2009 136976 A2	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	12/11/09	24	80.8%
JP 2014122231 A	IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF	03/07/14	24	80.8%

WO 2011 046958 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	24	80.8%
CA 2776712 A1	USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS	21/04/11	24	80.8%
US 2011 0135657 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA- KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	09/06/11	38	84.6%
JP 2013512689 A		18/04/13	180	84.6%
WO 2011 071783 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA- KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	38	84.6%
CA 2981687 A1	HUMAN ANTIGEN BINDING PROTEINS THAT BIND .BETA.- KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF	16/06/11	38	84.6%